Generated by DeepSeek V3.2| LSD | |
|---|---|
| IUPAC name | (6aR,9R)-N,N-diethyl-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide |
| CAS number | 50-37-3 |
| PubChem | 5761 |
| DrugBank | DB04829 |
LSD. Lysergic acid diethylamide, commonly known by its three-letter abbreviation, is a potent psychedelic substance renowned for its profound psychological effects. It is derived from lysergic acid, which is found in the ergot fungus, a parasite that grows on rye and other grains. First synthesized in 1938 by Swiss chemist Albert Hofmann at the Sandoz laboratories, its psychoactive properties were discovered accidentally five years later. The compound acts primarily on the brain's serotonin receptors, leading to altered perceptions, thoughts, and feelings.
The modern history of the substance began in the Basel laboratories of Sandoz, where Albert Hofmann first synthesized it while researching derivatives of ergot alkaloids for potential medicinal applications. Its psychedelic effects were unknown until 1943, when Hofmann accidentally ingested a small amount and experienced its powerful psychoactive properties, an event later commemorated as "Bicycle Day." Sandoz subsequently marketed it under the trade name Delysid in 1947 for psychiatric research, promoting its use in psycholytic therapy and as a tool to model psychosis. Throughout the 1950s and early 1960s, it was studied extensively by psychiatrists like Humphry Osmond and became central to the work of the Harvard Psilocybin Project, led by figures such as Timothy Leary and Richard Alpert. Its association with the counterculture of the 1960s, particularly events like the Human Be-In and music festivals such as Woodstock, led to widespread non-medical use and subsequent prohibition. The Controlled Substances Act of 1970 in the United States classified it as a Schedule I drug, severely restricting legal research for decades.
Chemically, it is a semi-synthetic compound belonging to the ergoline family. Its structure is based on the indole ring system, characteristic of many tryptamine psychedelics, and is derived from lysergic acid, a precursor obtained from the Claviceps purpurea fungus. The molecule is typically produced as a crystalline solid and is often converted into a salt, such as tartrate, for stability. It is exceptionally potent, with active doses measured in micrograms, and is sensitive to oxygen, ultraviolet light, and chlorine, which can degrade the compound. Analytical techniques like gas chromatography-mass spectrometry and nuclear magnetic resonance spectroscopy are used to identify and study its structure and purity.
The primary mechanism of action involves agonism, particularly partial agonism, at the 5-HT2A receptor, a subtype of the serotonin receptor in the brain. It also binds with high affinity to other serotonin receptor subtypes, including 5-HT1A, 5-HT2C, and 5-HT5A. Upon binding, it triggers a cascade of neuronal signaling that increases glutamate release in the cerebral cortex, particularly in layers IV and V. This leads to a disruption of normal thalamic gating and increased communication between brain regions that do not typically interact, a state often described as increased functional connectivity. The drug is metabolized in the liver, primarily via cytochrome P450 enzymes, and its metabolites are excreted in the bile and urine.
Subjective effects, which begin 30 to 90 minutes after ingestion and can last up to 12 hours, include dramatically altered sensory perception, such as visual hallucinations, synesthesia, and distorted sense of time. Cognitive effects may involve accelerated thought, introspection, and mystical-type experiences, while emotional effects range from euphoria and awe to anxiety and paranoia, often described as a "bad trip." Physiological effects can include mydriasis (pupil dilation), increased heart rate and blood pressure, elevated body temperature, and hyperreflexia. While it is not considered addictive and has extremely low toxicity, acute adverse reactions can include panic attacks and, in rare cases, lasting perceptual disturbances known as Hallucinogen Persisting Perception Disorder.
Following a decades-long hiatus after prohibition, regulatory approval for clinical research resumed in the 2000s. Contemporary studies, often led by organizations like the Multidisciplinary Association for Psychedelic Studies, have investigated its potential in treating conditions such as treatment-resistant depression, anxiety associated with life-threatening illness, and cluster headaches. Recent Phase II trials, including work by researchers at institutions like University Hospital Basel and Imperial College London, have shown promising results for its use in psychotherapy, often in conjunction with psychological support. These studies suggest that the substance may help facilitate emotional breakthrough and enhance the therapeutic process, leading to sustained reductions in symptoms for some patients.
The drug has had a profound and lasting impact on global culture, inextricably linked to the anti-war movement and the hippie subculture of the 1960s. It influenced a vast array of musicians, including The Beatles, Pink Floyd, and The Grateful Dead, and authors like Ken Kesey, whose Merry Pranksters staged the Acid Tests. Its portrayal in media, from films like Easy Rider to the writings of Aldous Huxley in The Doors of Perception, shaped public perception. In the late 20th century, it became associated with rave culture and the electronic dance music scene. Its legal status remains contentious, fueling ongoing debates about drug policy reform, with advocacy groups such as the Beckley Foundation pushing for evidence-based rescheduling and expanded research. Category:Drugs